Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
* * $AIM Video Chart 09-22-2020 * *
Link to Video - click here to watch the technical chart video
I have to agree. No position.
Lock your Shares now to 6.50 PT $$$$
BREAKING NEWS: $AIM AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands
Median survival approximately two-fold higher in Ampligen arm compared to historical controls; AIM to seek FDA Fast Track designation and orphan drug status in late stage pancreatic cancer OCALA, FL / ACCESSWIRE / September 22, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announ...
In case you are interested AIM - AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands
I'll pass on this one.
Great call. Heavy share dumping this morning.
News caught my eye. But it's trading like a pump-n-dump.
Bonzaiiiiii folow the $$$$
went short 2.77. gap needs filled. chronic fatigue syndrome. they been scamming shares for a decade
AIM LOOKING GOOD TODAY. AIM DRUG GROUP STUDY RESULTS IS 200% BETTER THAN HISTORICAL GROUP IN PANCREATIC CANCER.
Covid vill be heating up ahain.
Folow the $$$$
AIM ImmunoTech Inc (AIM)
1.77 ? -0.07 (-3.80%)
Volume: 2,799,831 @09/04/20 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.6 - 1.88
AIM Detailed Quote
* * $AIM Video Chart 08-27-2020 * *
Link to Video - click here to watch the technical chart video
News; $AIM AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19
OCALA, FL / ACCESSWIRE / August 27, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) is pleased to announce that it has identified an effective in vitro model at The Institute for Antiviral Research at Utah State University for testing Ampligen, a dsRNA TLR3 agonist, and the results show t...
Read the whole news AIM - AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19
$aim $2.12 v -0.05 (-2.30%)
Volume: 1,306,273 @08/26/20 8:00:00 PM EDT
Awesome ! Let’s get active , wouldn’t want to lose any money !!
$AIM $AIM $AIM
Nice bounce this morning ...AIM
Been trading this one at higher levels.
Was, luckily, out before this last drop.
But, I like the risk reward here.....added back during this dip.
AIM
AIM ImmunoTech Inc (AIM)
2.55 ? 0.01 (0.39%)
Volume: 3,524,185 @08/14/20 8:00:00 PM EDT
Bid Ask Day's Range
- - 2.44 - 2.63
AIM Detailed Quote
$AIM AIM ImmunoTech Inc (AIM)
2.92 ? 0.15 (5.42%)
Volume: 3,939,677 @07/31/20 8:00:00 PM EDT
Bid Ask Day's Range
- - 2.73 - 3.04
AIM Detailed Quote
$aim $2.92 ^ 0.15 (5.42%)
Volume: 3,936,670 @07/31/20 7:50:43 PM EDT
$AIM, anything wit covid-19 in it is serious
$AIM, IT IS INTERESTING PRODUCT
RE;
AIM ImmunoTech Inc (AIM)
2.915 ? 0.145 (5.23%)
Volume: 3,580,170 @07/31/20 3:22:40 PM EDT
Bid Ask Day's Range
- - 2.73 - 3.04
AIM Detailed Quote
An update from this company could send this parabolic.
https://finance.yahoo.com/news/aim-immunotech-present-snn-network-105500124.html
Loading before Mondays presentation.
I my eyes here now mick
AIM ImmunoTech Inc (AIM)
3.065 ? -0.005 (-0.16%)
Volume: 4,434,776 @07/24/20 8:00:00 PM EDT
Bid Ask Day's Range
- - 2.81 - 3.16
AIM Detailed Quote
News: $AIM Ergomed H1 2020 Trading Update
PRESS RELEASE Ergomed H1 2020 Trading Update EBITDA for FY 2020 expected to be materially ahead of market expectations Integrated pharmaceutical services business demonstrates resilience during Covid-19 Total revenue growth of 14.8% over H1 2019; like for like service f...
Read the whole news AIM - Ergomed H1 2020 Trading Update
* * $AIM Video Chart 07-20-2020 * *
Link to Video - click here to watch the technical chart video
I was referring to whytestocks postings...
wrong pump and dump company
Moderators is this Spamming the board...News: $AIM Marimaca Copper: Appointment of Company President
News: $AIM Marimaca Copper: Appointment of Company President
VANCOUVER, British Columbia, July 20, 2020 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (“Marimaca Copper” or the “Company”) (TSX: MARI) is pleased to announce the appointment of Mr. Hayden Locke as President of Marimaca Copper, effective immediately. Mr. L...
Read the whole news AIM - Marimaca Copper: Appointment of Company President
AIM earnings are Aug. 10th...
The charts are supporting even higher prices... wow
Big money is in the stock now..... something is up....
streetsmartstocks Thursday, 07/16/20 01:00:17 PM
Re: bleu22 post# 1920 0
Post #
1921
of 1932
As I posted last week, I what I saw on my charts is going to send this to Mars BOOM! ALL MY CUSTOM INDICATORS SHOW $6/7 NEXT WEEK IF NOT TOMORROW
Don't believe that is ours
News: $AIM AMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
AMRYT PHARMA PLC (“ Amryt ” or the “ Company ”) AMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020 DUBLIN, Ireland, and Boston MA, July 20 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company d...
Read the whole news AIM - AMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
News: $AIM Galantas Closes Private Placement
TORONTO, July 20, 2020 (GLOBE NEWSWIRE) -- Galantas Gold Corporation ( TSXV & AIM: Symbol GAL ) (the “Company”), the AIM and TSXV quoted gold producer and explorer with a 100% interest in Northern Ireland’s Omagh gold mine, announces that the proposed p...
In case you are interested AIM - Galantas Closes Private Placement
News: $AIM Angle Plc Announces Study: Parsortix Use in Metastatic Breast Cancer
RESEARCH STUDY INVESTIGATES USE OF PARSORTIX LIQUID BIOPSY FOR METASTATIC BREAST CANCER PATIENTS Pilot study compared Parsortix liquid biopsy to tissue biopsy of a metastatic site Potential actionable therapeutic targets were found in the Parsortix liquid biopsy that were missed in...
Got this from AIM - Angle Plc Announces Study: Parsortix Use in Metastatic Breast Cancer
3.73 now as AIM is aktivating.
4 doller comoung
$aim $3.04 v -0.08 (-2.56%)
Volume: 8,013,991 @07/17/20 8:00:00 PM EDT
AIM...$3.04...Triple Top Breakout setting up here on the Consolidation Channel Break...as the Bollies get stretched...Looking for $7 plus...imo..we shall see..
Chart...http://schrts.co/MtnvtFrH
georgie18 Thursday, 07/09/20 07:13:52 AM
Re: None 0
Post #
1906
of 1925
AIM...$2.85 in the P/M...AIM been looking like she wants to breakout lately...imo...we shall see...
[7:13 AM]
georgie1806/25/2020
AIM...$2.58...A/H...Breakout setting up here ...imo...we shall see...
With you till at least 7
Followers
|
58
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2076
|
Created
|
04/27/12
|
Type
|
Free
|
Moderators |
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers,
as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids
and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.
AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3).
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment)
or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
We operate a 30,000 sq. ft. facility in New Brunswick, NJ with the objective of producing Ampligen® and Alferon®.
We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and
expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.
April 4th, 2019
CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]
March 25th, 2019
Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the [...]
March 9th, 2020
AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus
On March 9 th we announced that Japan’s National Institute of Infectious [...]
https://aimimmuno.com/all-articles/
AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19 SNNLive caught up with Thomas Equels, CEO AIM ImmunoTech Inc. Watch the full video here. [...]
AIM ImmunoTech Announces the National Cancer Institute's Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers We recently announced [...]
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic We recently announced the AIM ImmunoTech team is working [...]
AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus On March 9 th we announced that Japan’s National Institute of Infectious [...]
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® has in the clinic demonstrated the potential for standalone efficacy in a number of solid tumors.
We have also seen success in increasing survival rates and efficacy in the treatment of animal tumors when
Ampligen® is used in combination with checkpoint blockade therapies.
This success in the field of immuno-oncology has guided our focus toward the potential use of Ampligen®
as a combinational therapy for the treatment of a variety of solid tumor types.
There are currently multiple Ampligen® clinical trials — both underway and planned — at major cancer research centers around the country.
Ampligen ® is also being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP)
approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). AIM ImmunoTech
is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the U.S.
In August 2016, we received approval of our NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)
for commercial sale of Ampligen® in the Argentine Republic for the treatment of severe CFS. With regulatory approval in Argentina,
Ampligen® is the world’s only approved therapeutic for ME/CFS.
We continue to pursue our Ampligen New Drug Application, or NDA, for the treatment of CFS with the Food and Drug Administration, or FDA.
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory
(resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
Certain types of human papilloma viruses cause GW. AIM ImmunoTech also has approval from ANMAT for the treatment of
refractory patients that failed or were intolerant to treatment with recombinant interferon in Argentina.
We have developed and, with proper funding, will be seeking FDA Pre-Approval Inspection of a high-volume, high-efficiency,
upgraded manufacturing process to allow for the commercial viability of Alferon®.
Pipeline
https://aimimmuno.com/pipeline/
Please direct your inquiries regarding business development and licensing opportunities to: info@AIMImmunoTech.com
2117 SW Highway 484
Ocala, FL 34473
Book/sh | 1.96 |
Cash/sh | 0.84 |
Debt/Eq | 0.19
|
Shs Outstand | 32.62M |
Shs Float | 28.77M |
Short Float | 5.87% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |